Cargando…

Advancing leukemia diagnostics: Role of Next Generation Sequencing (NGS) in acute myeloid leukemia

AML diagnostics, initially based solely on morphological evaluation, now relies on multiple disciplines to reach its full potential. Only by integrating the results of cytomorphology, cytochemistry, immunophenotyping, cytogenetics and molecular genetics it is possible to fulfil WHO classification an...

Descripción completa

Detalles Bibliográficos
Autor principal:	Haferlach, Torsten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	PAGEPress Publications, Pavia, Italy 2020
Materias:	How to manage - Acute Myeloid Leukemia
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520852/ https://www.ncbi.nlm.nih.gov/pubmed/33042506 http://dx.doi.org/10.4081/hr.2020.8957

Ejemplares similares

Acute myeloid leukemia
por: Haferlach, Torsten
Publicado: (2019)

AML-075: Converting In-Person Research Procedures to a Virtual Platform During the COVID-19 Pandemic in Newly Diagnosed Acute Myeloid Leukemia Patients
por: Tinsley, Sara, et al.
Publicado: (2021)

AML-145: Outcomes of Induction Therapy in Patients with Acute Myeloid Leukemia During Covid-19 Pandemic: A Retrospective Study from a Tertiary Care Cancer Centre
por: Iqbal, Asif, et al.
Publicado: (2021)

Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4
por: Kayser, Sabine, et al.
Publicado: (2022)

Analysis of rare driving events in pediatric acute myeloid leukemia
por: Noort, Sanne, et al.
Publicado: (2022)

Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications
por: Nilsson, Christer, et al.
Publicado: (2022)

Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning
por: Eckardt, Jan-Niklas, et al.
Publicado: (2022)

Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia
por: Kuusanmäki, Heikki, et al.
Publicado: (2022)

FLT4 as a marker for predicting prognostic risk of refractory acute myeloid leukemia
por: Lee, Ji Yoon, et al.
Publicado: (2023)

Comprehensive molecular and clinical characterization of NUP98 fusions in pediatric acute myeloid leukemia
por: Bertrums, Eline J. M., et al.
Publicado: (2023)

Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia
por: Kayser, Sabine, et al.
Publicado: (2023)

Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial
por: Russell, Nigel H., et al.
Publicado: (2021)

Clinical and biological impact of ATP-binding cassette transporter activity in adult acute myeloid leukemia
por: Sourdeau, Elise, et al.
Publicado: (2022)

The NADPH oxidase NOX2 is a marker of adverse prognosis involved in chemoresistance of acute myeloid leukemias
por: Paolillo, Rosa, et al.
Publicado: (2022)

Time spent at home among older adults with acute myeloid leukemia receiving azacitidine- or venetoclax-based regimens
por: Jensen, Christopher E., et al.
Publicado: (2022)

Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia
por: Gutman, Jonathan A., et al.
Publicado: (2023)

Treatment free remission in chronic myeloid leukemia: Lights and shadows
por: Molica, Matteo, et al.
Publicado: (2020)

A self-assembled leucine polymer sensitizes leukemic stem cells to chemotherapy by inhibiting autophagy in acute myeloid leukemia
por: Xu, Xi, et al.
Publicado: (2022)

Clinical relevance of proteomic profiling in de novo pediatric acute myeloid leukemia: a Children’s Oncology Group study
por: Hoff, Fieke W., et al.
Publicado: (2022)

Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy
por: Zhang, Weiguo, et al.
Publicado: (2022)

Clinical value of new drugs in acute myeloid leukemia
por: Ossenkoppele, Gert
Publicado: (2019)

A novel CD34-specific T-cell engager efficiently depletes acute myeloid leukemia and leukemic stem cells in vitro and in vivo
por: Arruda, Lucas C. M., et al.
Publicado: (2022)

Improved outcomes with “7+3” induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data
por: Othus, Megan, et al.
Publicado: (2022)

Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia/myelodysplastic syndromes after a first transplantation
por: Yerushalmi, Yaara, et al.
Publicado: (2022)

AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill F LT 3-ITD acute myeloid leukemia
por: Post, Sean M., et al.
Publicado: (2021)

Acute myeloid leukemia: negative prognostic impact of early blast persistence can be in part overcome by a later remission prior to post-induction therapy
por: Ihlow, Jana, et al.
Publicado: (2021)

COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)
por: Marchesi, Francesco, et al.
Publicado: (2022)

A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia
por: Pratz, Keith W., et al.
Publicado: (2022)

Simultaneous inhibition of Sirtuin 3 and cholesterol homeostasis targets acute myeloid leukemia stem cells by perturbing fatty acid β-oxidation and inducing lipotoxicity
por: O’Brien, Cristiana, et al.
Publicado: (2023)

The retinoic acid receptor co-factor NRIP1 is uniquely upregulated and represents a therapeutic target in acute myeloid leukemia with chromosome 3q rearrangements
por: Grasedieck, Sarah, et al.
Publicado: (2021)

Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia
por: Orvain, Corentin, et al.
Publicado: (2022)

Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy
por: Pabst, Thomas, et al.
Publicado: (2023)

Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2)
por: Richard-Carpentier, Guillaume, et al.
Publicado: (2023)

Chronic myeloid leukemia
por: Hantschel, Oliver
Publicado: (2019)

Clinical relevance of an objective flow cytometry approach based on limit of detection and limit of quantification for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial
por: Buccisano, Francesco, et al.
Publicado: (2022)

A risk score based on real-world data to predict early death in acute promyelocytic leukemia
por: Österroos, Albin, et al.
Publicado: (2022)

Molecular targeting of the UDP-glucuronosyltransferase enzymes in high-eukaryotic translation initiation factor 4E refractory/relapsed acute myeloid leukemia patients: a randomized phase II trial of vismodegib, ribavirin with or without decitabine
por: Assouline, Sarit, et al.
Publicado: (2023)

Persistent DNA damage and oncogenic stress-induced Trem1 promotes leukemia in mice
por: Li, Xue, et al.
Publicado: (2022)

Interplay between hypertriglyceridemia and acute promyelocytic leukemia mediated by the cooperation of peroxisome proliferator-activated receptor-α with the PML/RAR α fusion protein on super-enhancers
por: Wu, Shishuang, et al.
Publicado: (2022)

Signal peptide-CUB-EGF-like repeat-containing protein 1-promoted FLT3 signaling is critical for the initiation and maintenance of MLL-rearranged acute leukemia
por: Sahoo, Binay K., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_38niqdfj4scq68nr8o4cdphdmm